|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.980 USD | +1.71% |
|
+1.02% | +8.36% |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 339.9 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 66.25% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 152.7 | 27.55 | 153.2 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 149.32% | -81.96% | 456.01% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.69x | -2.63x | -2.79x |
| PBR | - | - | - | 0.78x | 0.99x | 1.32x | 1.13x | 1.59x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -1.2x | 0.47x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 814x | 697x | 25.2x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 366x | 56.5x | 11.4x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.2x | -0.19x | -1x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.22x | -0.19x | -1.06x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.46x | -0.2x | -1.02x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -68.3% | -503% | -98.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.109 | -1.134 | -1.066 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.4177 | 0.4875 | 13.49 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -126.9 | -144.2 | -153 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -125.4 | -144.8 | -144.5 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -121 | -138.1 | -137 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -187.1 | -312.3 | -186.7 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 2.980 | 2.980 | 2.980 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,046 | - | - |
| Announcement Date | 21/9/21 | 1/5/23 | 28/3/24 | 26/3/25 | 16/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.69x | 365.63x | -1.2x | -.--% | 340M | |
| 29.79x | 5.28x | 16.37x | 1.1% | 43.44B | |
| -19.84x | 293.52x | -18.08x | -.--% | 33.54B | |
| 20.77x | 2.44x | 10.54x | -.--% | 28.48B | |
| 39.19x | 3.88x | 24.86x | -.--% | 29.2B | |
| 29.31x | 7.59x | 19.53x | 0.42% | 25.34B | |
| 26.83x | 4.29x | 19.54x | -.--% | 13.05B | |
| 21.72x | 1.89x | 8.33x | 1.23% | 12.67B | |
| -20.58x | 13.55x | -20.17x | -.--% | 12.28B | |
| Average | 13.83x | 77.56x | 6.63x | 0.31% | 22.04B | |
| Weighted average by Cap. | 17.54x | 54.55x | 8.76x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
